华丽家族参股企业海和药物与大鹏药品达成授权合作

Core Points - Shanghai Haihe Pharmaceutical Co., Ltd. has entered into an exclusive licensing agreement with Japan's Daikyo Pharmaceutical Co., Ltd. for the development, production, and commercialization of the PI3Kα inhibitor, CYH33, in Japan [1] - This collaboration follows a previous agreement between Haihe Pharmaceutical and Daikyo Pharmaceutical regarding the MET inhibitor, Gomitil, which has successfully been approved for sale in both China and Japan [1] - The agreement will provide Haihe Pharmaceutical with an upfront payment, milestone payments based on development and sales, and royalties based on sales in Japan [1] Group 1 - The partnership highlights Daikyo Pharmaceutical's recognition of Haihe Pharmaceutical's research capabilities [2] - The collaboration reflects Haihe Pharmaceutical's strategy of "Chinese innovation, global layout," supported by the capital investment from Huayi Family [2] - Huayi Family's investment has facilitated Haihe Pharmaceutical's research and global expansion, enhancing the stability and speed of its innovative drug's international journey [2]